6,7-dihydroxy-4-oxo-1H-quinoline-3-carboxylic acid | 70393-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6,7-dihydroxy-4-oxo-1H-quinoline-3-carboxylic acid
• 英文别名: 6,7-dihydroxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid；1,4-Dihydro-6,7-dihydroxy-4-oxo-3-quinolinecarboxylic acid
• CAS: 70393-87-2
• 化学式: C₁₀H₇NO₅
• 分子量: 221.169
• InChiKey: NLBGQBKFPWERGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6,7-dihydroxy-4-oxo-1H-quinoline-3-carboxylic acid 在 三甲基氯硅烷 、 N,N-二异丙基乙胺 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  PHARMACEUTICAL COMPOSITION AND KIT CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM beta-LACTAMASE INHIBITORY COMPOUND AND ANTIBACTERIAL COMPOUND OR SALTS THEREOF

  摘要：

  本发明的目的是提供一种药物组合物和套装，该组合物和套装对革兰氏阴性菌和/或耐药革兰氏阴性菌具有强烈的抗菌活性。包含由通式[1]表示的化合物（每个参考数字的含义如本规范中所述）或其盐和一种或多种从β-内酰胺酶抑制剂和抗菌化合物中选择的化合物的药物组合物和套装对革兰氏阴性菌，如铜绿假单胞菌和/或耐多种药物的铜绿假单胞菌等耐药革兰氏阴性菌具有强烈的抗菌活性，并且对于治疗由这些细菌引起的感染是有用的。

  公开号：

  US20220241249A1
• 作为产物：
  描述：

  5,8-二氢-8-氧代-2H-1,3-二氧杂环戊并(4,5-g)喹啉-7-羧酸 在 三溴化硼 作用下， 反应 24.0h， 生成 6,7-dihydroxy-4-oxo-1H-quinoline-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues

  摘要：

  Cephalosporins with new catechol substituents at C-3' have been synthesized, including novel compounds with C-3' carbon-carbon bonds. Many of these compounds have high potency against Gram-negative bacteria, in particular against resistant strains like Pseudomonas aeruginosa. Structure-activity relationships are discussed in terms of their dependence on the pK(a) of the C-3' catechol and also in terms of steric and conformational factors of the C-3' substituent. The best overall properties were found in compounds with a bulky and/or conformationally restricted acidic C-3' catechol.

  DOI：

  10.1021/jm00092a014

文献信息

• Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0420069A2

  公开（公告）日：1991-04-03

  Antibacterial activity has been found in compounds of the formula and pharmaceutically acceptable salts thereof, wherein: A is a bond or alkylene; Q completes a 5- or 6-membered saturated or aromatic heterocyclic ring optionally having an oxo substituent and and comprising up to two heteroatoms independently selected from N, NRs, S, O. Y is hydrogen, amino, hydroxy, carboxyl (provided that when Y is carboxyl the heterocyclic ring is not part of a quinoxaline or quinoline group), halogen, carboxamide, or nitrile; M⊕ is hydrogen or a cation; and the remaining symbols are as defined in the specification.

  式中的化合物及其药物可接受盐具有抗菌活性。 及其药学上可接受的盐，其中 A 是键或亚烷基； Q 完成一个 5 或 6 元饱和或芳香杂环，任选具有一个氧代基，并包含最多两个独立选自 N、NRs、S、O 的杂原子。 Y 是氢、氨基、羟基、羧基（条件是当 Y 是羧基时，杂环不是喹喔啉或喹啉基团的一部分）、卤素、羧酰胺或腈； M⊕ 是氢或阳离子；其余符号如说明书中所定义。
• PHARMACEUTICAL COMPOSITION AND KIT CHARACTERIZED BY CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM ?-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE
  申请人：FUJIFILM Corporation

  公开号：EP4039257A1

  公开（公告）日：2022-08-10

  An object of the present invention is to provide a pharmaceutical composition and a kit which exhibit strong antibacterial activity against Gram-negative bacteria and/or drug-resistant Gram-negative bacteria. A pharmaceutical composition and a kit containing a compound represented by General Formula [1] (the meaning of each reference numeral is as described above in the present specification) or a salt thereof and one or more compounds selected from a β-lactamase inhibitory compound and an antibacterial compound have strong antibacterial activity against Gram-negative bacteria such as Pseudomonas aeruginosa and/or drug-resistant Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa, and are useful for treating infections caused by these bacteria.

  本发明的目的是提供一种药物组合物和一种试剂盒，对革兰氏阴性细菌和/或耐药革兰氏阴性细菌具有很强的抗菌活性。 一种药物组合物和一种试剂盒含有通式[1]代表的化合物（各参考数字的含义如本说明书上文所述）或其盐和一种或多种选自β-内酰胺酶抑制化合物和抗菌化合物的化合物，对革兰氏阴性菌如铜绿假单胞菌和/或耐药革兰氏阴性菌包括耐多药铜绿假单胞菌具有很强的抗菌活性，可用于治疗由这些细菌引起的感染。
• US5019570A
  申请人：——

  公开号：US5019570A

  公开（公告）日：1991-05-28
• US5232918A
  申请人：——

  公开号：US5232918A

  公开（公告）日：1993-08-03
• US5318963A
  申请人：——

  公开号：US5318963A

  公开（公告）日：1994-06-07